Bespoke Extracts Files 10-Q, Confirms Smaller Reporting Status

TL;DR

**BSPK is a tiny, high-risk play with minimal public info – avoid unless you love speculation.**

AI Summary

Bespoke Extracts, Inc. (BSPK) filed its 10-Q for the quarter ended March 31, 2025, indicating it is a non-accelerated filer, a smaller reporting company, and an emerging growth company. The company confirmed it has filed all required reports over the past 12 months and has been subject to filing requirements for the past 90 days. It also confirmed electronic submission of all Interactive Data Files. The filing does not provide specific revenue or net income figures, nor does it detail key business changes or strategic outlook. However, its classification as a smaller reporting company and emerging growth company suggests a relatively early stage of development or limited financial scale. The company is not a shell company, which is a positive indicator. Risks are implied by its smaller company status and lack of publicly traded securities.

Why It Matters

For investors, BSPK's status as a non-accelerated, smaller reporting, and emerging growth company signals higher risk and potentially less liquidity compared to larger firms. This classification means less stringent reporting requirements, which could lead to less transparency. Employees might face greater job uncertainty due to the inherent volatility of smaller companies. Customers may see less product innovation or market reach. Competitively, BSPK is likely a niche player, facing significant challenges from larger, more established pharmaceutical preparation companies.

Risk Assessment

Risk Level: high — The company is classified as a 'smaller reporting company' and an 'emerging growth company,' indicating a higher inherent risk profile due to its size and developmental stage. Additionally, Bespoke Extracts, Inc. has 'None' listed for securities registered pursuant to Section 12(b) of the Act, meaning its securities are not traded on a national exchange, which significantly limits liquidity and price discovery for investors.

Analyst Insight

Investors should exercise extreme caution with BSPK due to its small size, emerging growth status, and lack of exchange-listed securities. This stock is highly speculative; consider it only if you have a high-risk tolerance and are prepared for potential illiquidity and significant capital loss.

Financial Highlights

debt To Equity

Not Disclosed

revenue

Not Disclosed

operating Margin

Not Disclosed

total Assets

Not Disclosed

total Debt

Not Disclosed

net Income

Not Disclosed

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

Not Disclosed

revenue Growth

Not Disclosed

Key Numbers

• 20250331 — Conformed Period of Report (The quarter for which the 10-Q was filed, indicating recent financial activity.)
• 000-52759 — Commission File Number (Unique identifier for Bespoke Extracts, Inc. with the SEC.)
• None — Securities Registered (Indicates no securities are registered pursuant to Section 12(b) of the Act, meaning no national exchange listing.)
• Yes — Filed all reports (The company confirmed it has filed all required reports in the past 12 months, indicating compliance.)
• Yes — Submitted Interactive Data File (The company confirmed electronic submission of data, showing regulatory compliance.)

Key Players & Entities

• Bespoke Extracts, Inc. (company) — Registrant filing the 10-Q
• SEC (regulator) — Recipient of the 10-Q filing
• 000-52759 (dollar_amount) — Commission File Number for Bespoke Extracts, Inc.
• Nevada (company) — State of incorporation for Bespoke Extracts, Inc.
• Aurora, CO (company) — Location of Bespoke Extracts, Inc.'s principal executive offices
• DiMi Telematics International, Inc. (company) — Former name of Bespoke Extracts, Inc.
• FIRST QUANTUM VENTURES INC (company) — Former name of Bespoke Extracts, Inc.
• March 31, 2025 (dollar_amount) — End date of the quarterly period reported in the 10-Q
• 2025-06-30T00:00:00.000Z (dollar_amount) — Filing date of the 10-Q
• 03 Life Sciences (company) — Organization name associated with the filing

FAQ

Risk Factors

• Emerging Growth Company Status [low — regulatory]: As an emerging growth company and smaller reporting company, Bespoke Extracts, Inc. may not be required to comply with certain new or revised accounting standards. This could lead to a difference in financial reporting compared to larger, more established companies, potentially impacting comparability for investors.
• Lack of Exchange Listing [medium — market]: The company has no securities registered pursuant to Section 12(b) of the Act, indicating no listing on a national securities exchange. This suggests limited liquidity and potentially higher volatility for any traded shares, making it harder for investors to buy or sell significant positions.
• Limited Financial Disclosure [medium — financial]: The 10-Q filing does not provide specific revenue or net income figures, nor does it detail key business changes or strategic outlook. This lack of detailed financial information makes it challenging for investors to assess the company's performance and financial health.
• Early Stage of Development [medium — operational]: The classification as a smaller reporting company and emerging growth company implies a relatively early stage of development or limited financial scale. This stage often comes with inherent operational risks, including challenges in scaling operations, market penetration, and achieving profitability.

Industry Context

Bespoke Extracts, Inc. operates within the Pharmaceutical Preparations (SIC 2834) industry. This sector is characterized by significant research and development, stringent regulatory oversight from bodies like the FDA, and a competitive landscape with both large established players and smaller niche companies. Trends include advancements in drug discovery, personalized medicine, and increasing demand for specialized pharmaceutical products.

Regulatory Implications

As a non-accelerated filer, smaller reporting company, and emerging growth company, Bespoke Extracts, Inc. benefits from scaled disclosure requirements. However, this status also implies a lack of extensive financial data publicly available, which can increase information asymmetry for investors and potentially heighten scrutiny regarding compliance and operational transparency.

What Investors Should Do

1. Seek additional financial disclosures
2. Monitor industry trends and competitive landscape
3. Assess liquidity and trading risks
4. Evaluate operational viability

Key Dates

• 2025-03-31: Quarterly Period End — This date marks the end of the reporting period for the 10-Q filing, reflecting the company's financial status and operations as of this point.
• 2025-06-30: 10-Q Filing Date — This is the date Bespoke Extracts, Inc. filed its quarterly report, indicating the timeliness of its regulatory disclosures.
• 2012-03-19: Name Change from DiMi Telematics International, Inc. — Indicates a significant corporate restructuring or strategic shift in the company's history.
• 2007-11-06: Name Change from FIRST QUANTUM VENTURES INC — Further historical context on corporate identity changes, potentially related to evolving business strategies.

Glossary

Non-accelerated filer

A filer that does not meet the requirements to be classified as an accelerated filer or a large accelerated filer, typically based on public float and filing history. (Indicates Bespoke Extracts, Inc. is subject to less stringent SEC reporting requirements compared to larger companies.)

Smaller reporting company

A company that meets certain criteria related to public float and annual revenues, allowing for scaled disclosure requirements. (Suggests Bespoke Extracts, Inc. has a limited market capitalization and revenue, impacting the depth of financial information provided.)

Emerging growth company

A company that has total annual gross revenues of less than $1.235 billion during its most recently completed fiscal year and meets other criteria, allowing for certain regulatory accommodations. (Highlights that Bespoke Extracts, Inc. is in an early stage of growth and benefits from relaxed reporting and compliance rules.)

Section 12(b) of the Act

Refers to the section of the Securities Exchange Act of 1934 that requires securities to be registered with the SEC if they are to be traded on a national securities exchange. (The absence of securities registered under this section means Bespoke Extracts, Inc. is not listed on a major stock exchange.)

Interactive Data File

Electronic files submitted to the SEC in a standardized format (like XBRL) that allows for automated processing and analysis of financial data. (Confirms Bespoke Extracts, Inc. is compliant with modern electronic filing standards.)

Shell company

A company with no or nominal operations, and often with minimal assets, whose primary purpose is to serve as a vehicle for financing or other transactions. (The explicit statement that Bespoke Extracts, Inc. is not a shell company is a positive indicator of legitimate business operations.)

Year-Over-Year Comparison

This filing does not contain specific comparative financial data such as revenue, net income, or margin changes from the previous year's filing. The company's classification as a non-accelerated filer, smaller reporting company, and emerging growth company remains consistent, suggesting no significant change in its reporting status or scale. No new material risks were explicitly detailed in the provided excerpt, but the inherent risks associated with smaller, less-established companies persist.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on June 30, 2025 regarding Bespoke Extracts, Inc. (BSPK).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR